Drug Pricing 'Deeper Dive' Planned By Senate Cmte. As Industry Avoids First Blood
Hearings in July and the fall will follow, but if the first session was any indication, industry doesn't have anything to worry about.
You may also be interested in...
Gottlieb: Real Risk Of Congressional Action If Anti-Competitive Actions Continue
To remain shielded from political forces that could change incentives, pharmaceutical industry must adopt 'a certain set of values,' US FDA Commissioner says.
Drug Pricing Hearing In Senate Postponed, Handing Innovators Another Victory
First hearing in Sen. Alexander's committee was dominated by Democrat complaints about Obamacare repeal; now that there's an actual bill to criticize, the next one might have been even worse, but regardless of the reason, the postponement means innovator prices get to stay out of the spotlight once again.
FDA Drug Pricing Policy Offers Short-Term PR Gain, More Long-Term Actual Benefit
Prioritizing ANDAs entering markets with fewer than three approved generics not expected to become a major advantage until first-cycle clearances increase.